Esperion Therapeutics, Inc. 8-K/A

What Happened

• Esperion Therapeutics, Inc. (ESPR) filed an amended Form 8‑K on June 18, 2026 to provide the required financial statements and pro forma financial information that were not included in its Original Report. The amendment was made under Items 9.01(a)(3) and 9.01(b)(2), allowing the company up to 71 calendar days to file those materials.
• The amendment only supplies the missing financial statements and pro forma information; it does not otherwise modify or update the substance of the Original Report and should be read together with that Original Report.

Key Details

• Filing date of amendment: June 18, 2026.
• Purpose: furnish required financial statements and pro forma financial information within the 71‑day extension permitted by Item 9.01.
• Scope: relates specifically to Item 9.01 (Financial Statements and Exhibits); no other items (e.g., earnings, executive changes, mergers) were changed.
• The amendment affirms that, aside from adding the financials/pro forma disclosures, the Original Report remains unchanged.

Why It Matters

• For investors, this amendment completes the disclosure record by providing the financial statements and pro forma data required to assess the financial impact of whatever transaction or event was described in the Original Report.
• The filing itself is administrative rather than substantive — it does not alter prior disclosures — but investors should review the newly furnished financial statements and pro forma information (together with the Original Report) to evaluate any effects on Esperion’s financial position or results.